SG11201502626PA - Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors - Google Patents

Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Info

Publication number
SG11201502626PA
SG11201502626PA SG11201502626PA SG11201502626PA SG11201502626PA SG 11201502626P A SG11201502626P A SG 11201502626PA SG 11201502626P A SG11201502626P A SG 11201502626PA SG 11201502626P A SG11201502626P A SG 11201502626PA SG 11201502626P A SG11201502626P A SG 11201502626PA
Authority
SG
Singapore
Prior art keywords
masitinib
cancer
treatment
patient subpopulations
subpopulations identified
Prior art date
Application number
SG11201502626PA
Other languages
English (en)
Inventor
Alain Moussy
Jean-Pierre Kinet
David Piquemal
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of SG11201502626PA publication Critical patent/SG11201502626PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201502626PA 2012-10-04 2013-10-04 Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors SG11201502626PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306214 2012-10-04
PCT/EP2013/070741 WO2014053650A1 (en) 2012-10-04 2013-10-04 Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Publications (1)

Publication Number Publication Date
SG11201502626PA true SG11201502626PA (en) 2015-05-28

Family

ID=47073382

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502626PA SG11201502626PA (en) 2012-10-04 2013-10-04 Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Country Status (20)

Country Link
US (1) US10238649B2 (ja)
EP (1) EP2903616B8 (ja)
JP (1) JP6234466B2 (ja)
KR (1) KR102149483B1 (ja)
CN (1) CN104968347A (ja)
AR (1) AR092899A1 (ja)
AU (1) AU2013326463B2 (ja)
BR (1) BR112015007144A2 (ja)
CA (1) CA2886979C (ja)
DK (1) DK2903616T3 (ja)
EA (1) EA037368B1 (ja)
ES (1) ES2656640T3 (ja)
IL (1) IL238107B (ja)
MX (1) MX369999B (ja)
NZ (1) NZ706420A (ja)
SG (1) SG11201502626PA (ja)
SI (1) SI2903616T1 (ja)
TW (1) TWI609686B (ja)
WO (1) WO2014053650A1 (ja)
ZA (1) ZA201503054B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052103A1 (en) * 2013-10-04 2016-08-10 AB Science Method for determining the prognosis of pancreatic cancer
EP3139959A1 (en) * 2014-05-08 2017-03-15 Oncoethix GmbH Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
JP7250312B2 (ja) * 2016-03-25 2023-04-03 エービー サイエンス 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用
CN107267454A (zh) * 2016-04-07 2017-10-20 北京京蒙高科干细胞技术有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
SG11201907023UA (en) * 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
WO2020092240A1 (en) * 2018-10-29 2020-05-07 Northwestern University Big data-driven personalized management of chronic pain
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
WO2020115261A1 (en) * 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN111759857A (zh) * 2020-06-30 2020-10-13 宁波市微循环与莨菪类药研究所 Gabrd甲基化靶点在制备抗***复吸药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0313165B8 (pt) 2002-08-02 2021-05-25 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US20090298061A1 (en) * 2005-07-29 2009-12-03 Siemens Healthcare Diagnostics Inc. Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy
US20100143935A1 (en) 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
JP2010515708A (ja) 2007-01-12 2010-05-13 アブ サイエンス 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療
AU2008214679A1 (en) 2007-02-13 2008-08-21 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
WO2011056963A1 (en) 2009-11-04 2011-05-12 The University Of North Carolina At Chapel Hill Methods and compositions for predicting survival in subjects with cancer
US20120309706A1 (en) 2010-02-01 2012-12-06 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
WO2012170640A1 (en) * 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy

Also Published As

Publication number Publication date
EP2903616B8 (en) 2018-02-07
WO2014053650A1 (en) 2014-04-10
DK2903616T3 (da) 2018-01-29
KR20150092739A (ko) 2015-08-13
JP2015532296A (ja) 2015-11-09
SI2903616T1 (en) 2018-02-28
TW201414475A (zh) 2014-04-16
IL238107B (en) 2018-03-29
CN104968347A (zh) 2015-10-07
EA037368B1 (ru) 2021-03-19
NZ706420A (en) 2018-08-31
MX2015004264A (es) 2015-10-12
KR102149483B1 (ko) 2020-08-28
EP2903616B1 (en) 2017-12-13
MX369999B (es) 2019-11-28
US20150272945A1 (en) 2015-10-01
BR112015007144A2 (pt) 2017-12-12
ZA201503054B (en) 2016-11-30
AR092899A1 (es) 2015-05-06
ES2656640T3 (es) 2018-02-27
EP2903616A1 (en) 2015-08-12
US10238649B2 (en) 2019-03-26
CA2886979A1 (en) 2014-04-10
AU2013326463B2 (en) 2018-01-18
JP6234466B2 (ja) 2017-11-22
AU2013326463A1 (en) 2015-04-16
TWI609686B (zh) 2018-01-01
EA201500373A1 (ru) 2016-02-29
CA2886979C (en) 2021-01-05

Similar Documents

Publication Publication Date Title
ZA201503054B (en) Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HK1254859A1 (zh) 治療乳腺癌的方法
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL232530B (en) A combination of factors for cancer treatment
IL239007B (en) Eribulin for use in the treatment of breast cancer
HK1214128A1 (zh) 癌症的治療
HK1199094A1 (en) Predictors for cancer treatment
HK1205254A1 (en) Methods of treatment of cancer
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
GB201208296D0 (en) Treatment of cancer
GB201110659D0 (en) composition for skin treatment
GB201110653D0 (en) Composition for skin treatment
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer